India’s pharmaceutical industry stands at a crossroads, facing both challenges and opportunities that could redefine its global standing. Experts emphasize the urgent need to enhance research-to-market timelines, fortify clinical trial infrastructures, and reduce dependence on imports of active pharmaceutical ingredients (APIs). This call to action comes as industry leaders advocate for a transformative shift towards biology-driven innovation.
The Need for a Robust RDI Ecosystem
At the forefront of discussions during PharmaMed 2026, the consensus emerged that a strong research, development, and innovation (RDI) ecosystem is crucial for future growth. As Satyaprakash T.L., Joint Secretary at the Department of Pharmaceuticals, articulated, the sector’s evolution should pivot from mere volume manufacturing to high-value, technology-centric outputs.
This paradigm shift requires an integrated approach that connects government policy, industry needs, and academic research. The provisions included in the Union Budget 2026–27 signal a commitment to building biological ecosystems, underscoring the necessity for collaboration among stakeholders.
Bridging the Gap Between Research and Commercialization
One of the pressing challenges in India’s pharmaceutical landscape is the time lag between laboratory innovations and their market introduction. The establishment of 1,000 clinical trial sites aims to streamline drug development processes, thereby reducing costs and enhancing efficiency. Addressing these bottlenecks is vital for fostering a more dynamic innovation pipeline.
Experts contend that minimizing reliance on imported APIs is equally critical, especially in essential sectors such as antibiotics and fermentation-based products. By advancing indigenous enzymatic engineering and promoting backward integration, India can build a more resilient supply chain.
Economic Impact and Social Responsibility
Vinod K. Paul, Member of NITI Aayog, highlighted the economic significance of the pharmaceutical sector, which constitutes 37 percent of total health expenditures and 63 percent of out-of-pocket costs. This reality positions the industry as a fundamental driver of affordability and financial protection in healthcare.
Government initiatives, such as the Ayushman Bharat program, have already begun reshaping access to healthcare services. However, Paul cautioned against complacency, noting that previous successes, including the rapid vaccine rollout during the Covid-19 pandemic, should not detract from the ongoing need for innovation investment.
Regulatory Reforms as Catalysts for Growth
Regulatory reforms are emerging as vital enablers of industry progress. A. Visala, Joint Drug Controller at CDSCO, pointed out that updated frameworks, including the Medical Devices Rules, 2017 and New Drugs and Clinical Trials Rules, have expedited approval processes and bolstered India’s international standing.
Moreover, India’s entry into advanced therapy medicinal products, such as cell and gene therapies, signifies a shift towards next-generation treatments. The impending implementation of updated good manufacturing practices (GMP) standards from January 2026 is expected to further enhance regulatory credibility and compliance.
Quality Assurance: A Shared Responsibility
Quality and compliance remain pivotal concerns for the industry. Gregory Smith, Country Director for India at the US FDA, emphasized that India hosts over 600 FDA-registered manufacturing facilities, the highest number outside the United States. This achievement underscores India’s crucial role in global supply chains.
Nevertheless, gaps persist in quality systems and laboratory controls. Smith advocated for a stronger compliance culture fostered through initiatives focused on quality management maturity. Mechanisms such as priority review processes and pre-check programs can enhance supply chain resilience and ensure consistent drug quality.
Transitioning to Innovation-Led Growth
Industry leaders assert that the future of the pharmaceutical sector lies in transitioning from cost-led growth to innovation-led expansion. Abhay Kumar Srivastava of Mankind Pharma suggested that the focus should shift toward developing biosimilars, complex generics, and long-acting therapies, all while ensuring affordability remains a priority.
He cautioned that backward integration is not just a strategic choice but a national security imperative. Dependence on external sources for critical starting materials can expose the sector to supply chain disruptions, making self-sufficiency essential.
Addressing Healthcare Disparities
Despite India’s reputation as the “pharmacy of the world,” significant gaps in domestic healthcare access persist. Ranjeet Mehta, CEO and Secretary General of PHDCCI, emphasized that bridging these disparities will require concerted efforts from policymakers, industry players, and technology innovators.
A recent knowledge report on national API capacity building outlines a long-term vision to fortify domestic manufacturing capabilities. Aligning India’s scientific talent, which includes numerous institutions and researchers, with supportive policies and industry investments could enable the nation to transition from a manufacturing hub to a leader in pharmaceutical innovation on the global stage.
Conclusion
As India’s pharmaceutical sector stands ready for transformation, the call for an accelerated RDI push cannot be overstated. By fostering innovation, enhancing regulatory frameworks, and prioritizing domestic manufacturing, India can secure its position as a global leader in pharmaceuticals. The journey ahead requires collaborative efforts and a commitment to quality, ensuring that the industry not only meets current demands but also anticipates future challenges.
- Key Takeaways:
- A robust RDI ecosystem is essential for growth.
- Reducing reliance on imported APIs is critical for supply chain resilience.
- Regulatory reforms can expedite drug approvals and enhance quality.
- Transitioning to innovation-led growth will define future success.
- Addressing healthcare access disparities is vital for social equity.
Read more → www.businessworld.in